Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 303Leukemia, Lymphocytic, Chronic, B-Cell 104Myelodysplastic Syndromes 63Recurrence 55Leukemia 42Neoplasms 41Lymphoma, Non-Hodgkin 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Mantle-Cell 32Multiple Myeloma 27Lymphoma, Large B-Cell, Diffuse 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Follicular 22Lymphoma 21Hematologic Neoplasms 20Lymphoma, B-Cell, Marginal Zone 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Burkitt Lymphoma 16Myeloproliferative Disorders 11Lymphoma, B-Cell 11Leukemia, Myeloid 11Neoplasm, Residual 10Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Chromosome 17 deletion 6Leukemia, B-Cell 5Immunoglobulin Light-chain Amyloidosis 5Breast Neoplasms 5

Interventions

Dexamethasone 21Calcium Dobesilate 10Melphalan 9Bortezomib 8Cyclophosphamide 7Lenalidomide 6pomalidomide 4miridesap 3daratumumab 3venetoclax 2ixazomib 2belantamab mafodotin 2Thalidomide 2Doxycycline 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1isatuximab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Pharmaceutical Preparations 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Amyloidosis × venetoclax × Clear all
NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT03000660 2020-08-21

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Tufts Medical Center

Phase 1 Terminated
3 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡